Randomised Trial: Enterosgel in the Treatment of Acute Diarrhoea in Adults

We present the results of a randomised controlled trial which assessed the efficacy and safety of the drug Enterosgel in the treatment of acute diarrhoea in adult patients (regardless of its origin—infectious or non-infectious).

Key Finding:

Compared to standard therapy (oral rehydration), the inclusion of Enterosgel in the treatment regimen led to a statistically significant reduction in the duration of diarrhoea (p=0.030).

Patients taking Enterosgel had a 64 per cent higher probability of a faster recovery. The mean time to the first non-watery stool in the treatment group was 27.1 hours (versus 38.9 hours in the control group).

Clinical Significance:

Enterosgel, acting as an oral adsorbent, is presumed to bind to bacterial toxins and enterotoxins, effectively removing them from the body. This not only accelerates the resolution of symptoms but may also reduce the risk of long term complications, such as post-infective irritable bowel syndrome.

The study also confirmed the high safety profile of the drug, demonstrating its good tolerability and the absence of serious adverse events in the treatment group.

Full Article: For detailed familiarization with the study methodology, statistical tables, and complete data, please follow the link below: Full Artricle